Search
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself.
Categories: Antivirals for treatment of HCV infectionsSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalapproval for the treatment of mTNBC patients who have undergone two or more prior therapies. … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated
Tolfenamic acid
go.drugbank.com/drugs/DB09216Approved[L1292] In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291] … [A31824] It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … [A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase Inhibitors, Non-SelectivePhenoxypropazine
go.drugbank.com/drugs/DB09251ApprovedWithdrawnIt was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeFET F-18
go.drugbank.com/drugs/DB15405InvestigationalFET F-18 is under investigation in clinical trial NCT01756352 (FET-PET for Evaluation of Response of Recurrent GBM to Avastin).
Synonyms: O-18F-fluoroethyl-L-tyrosine, O-(2-FLUOROETHYL)-L-TYROSINE F-18Alogliptin
go.drugbank.com/drugs/DB06203ApprovedInvestigationalAlogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). … It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013.
Mixtures: INCRESINA DUOCategories: Drugs Used in DiabetesFluoroacetic acid F-18
go.drugbank.com/drugs/DB15202InvestigationalFluoroacetic acid F-18 is under investigation in clinical trial NCT01320787 (18-F-Fluoroacetate as PET Imaging Agent).
Fluvoxamine
go.drugbank.com/drugs/DB00176ApprovedInvestigationalIt was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. … Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients.
Categories: Metabolic Side Effects of Drugs and Substances, Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome